Drug Trial Radar · NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
158
Planned (sponsor's estimate)
Start
Dec 30, 2024
Primary completion
Sep 30, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Conditions
- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
Interventions
ALN-BCATDrug
Administered by intravenous (IV) infusion
PembrolizumabDrug
Administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs)Time frame: From the time of first dose of study drug administration to 30-37 days after the last dose
- Severity of AEsTime frame: From the time of first dose of study drug administration to 30-37 days after the last dose
- Dose Escalation: Occurrence of Dose-limiting Toxicities (DLTs)Time frame: From the time of first dose of study drug administration up to 21 days
- Dose Expansion: Antitumor Activity as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to 30-37 Days after the last dose
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Phoenix, Arizona · Recruiting
Clinical Trial Site
La Jolla, California · Recruiting
Clinical Trial Site
Los Angeles, California · Recruiting
Clinical Trial Site
Jacksonville, Florida · Recruiting
Clinical Trial Site
Atlanta, Georgia · Recruiting
Clinical Trial Site
Chicago, Illinois · Recruiting
Clinical Trial Site
Ann Arbor, Michigan · Recruiting
Clinical Trial Site
Rochester, Minnesota · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Completed
Clinical Trial Site
Cleveland, Ohio · Recruiting
Clinical Trial Site
Pittsburgh, Pennsylvania · Recruiting
Clinical Trial Site
Dallas, Texas · Recruiting
Clinical Trial Site
Houston, Texas · Recruiting
Clinical Trial Site
San Antonio, Texas · Recruiting
Clinical Trial Site
Richmond, Virginia · Recruiting
Clinical Trial Site
Milan, Italy · Recruiting
Clinical Trial Site
Rozzano, Italy · Recruiting
Clinical Trial Site
Verona, Italy · Recruiting
Clinical Trial Site
Busan, South Korea · Recruiting
Clinical Trial Site
Seongnam, South Korea · Recruiting
Clinical Trial Site
Seongnam, South Korea · Recruiting
Clinical Trial Site
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.